UCB SA (OTCMKTS:UCBJF) Short Interest Up 21.4% in March

UCB SA (OTCMKTS:UCBJF) saw a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 584,000 shares, a growth of 21.4% from the March 15th total of 481,000 shares. Currently, 0.3% of the company’s shares are sold short. Based on an average trading volume of 700 shares, the days-to-cover ratio is currently 834.3 days.

UCB Price Performance

OTCMKTS:UCBJF opened at $150.70 on Monday. The stock has a fifty day simple moving average of $180.99 and a 200-day simple moving average of $184.23. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. UCB has a twelve month low of $126.05 and a twelve month high of $209.66.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.